1. ALLA AKTIER
  2. NYHETER
  3. SCANDINAVIAN REAL HEART

Scandinavian Real Heart

Nyheter Scandinavian Real Heart Nyheter alla bolag

Correction/Update of Q1 - 2024

MARKN.

Scandinavian Real Heart publishes an updated version of the Q1 report.
The new details in the update are:
Information on change in equity.
Calculated number of shares considering the future dilution from existing warrant programs.
Information on existing warrant program/incentive program for employees.
 
The above is information that has been communicated earlier, but has now been added to the report.

For more information, please contact:
Ina Laura Perkins, CEO
Phone: +46 (0) 70 406 49 21 
E-mail: inalaura.perkins@realheart.se
Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se

About Us
Scandinavian Real Heart is active in medical technology. The company conducts research and development in observations of the physiology of the heart. The development of the company's product, a complete artificial heart (TAH), takes place in collaboration with cardiac surgeons, researchers and engineers. The focus is on developing patented solutions that can imitate the blood circulation of the natural human heart. The solutions are intended for use by patients diagnosed with heart failure.

Attachments
Realheart Q1 2024 ENG 240513

Datum 2024-05-13, kl 14:30
Källa MFN
Bifogade filer
Realheart Q1 2024 ENG 240513
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!